Vertex Pharma misses sales estimates on weak demand for older CF treatments
(Reuters) – Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments. The drugmaker recorded a 35.4% fall…